Nereis. Interdisciplinary Ibero-American Journal of Methods, Modelling and Simulation.


Polylactic Acid Microspheres Labeled with 166Ho. An alternative to 90Y in the Treatment of Hepatic Carcinoma by Radioembolization


Liver tumors are an important health problem worldwide that on many occasions is associatedwith previous pathologies and risk factors such as viral hepatitis B and C, excessive alcohol consumptionand the increase in cases of non-alcoholic steatohepatitis, each increasingly relevant inindustrialized countries.In hepatocarcinomas not susceptible to surgical resection, brachytherapy is proving very effectiveagainst systemic and transarterial chemotherapy, developing new minimally invasiveregional treatments with less toxicity.Hepatic radioembolization is a form of brachytherapy consisting in the arterial administrationof microspheres labeled with beta negative emitting radionuclides that have little penetration inliver tissue, allowing the administration of high doses that cause cellular damage in tumor tissue,avoiding the irradiation of the contiguous healthy tissue.Among the most used microspheres are those of resin and/or glass marked with 90Y, althoughthe use of 166Ho on a biodegradable matrix of poly-L-lactic acid is currently increasing, the mainreasons lie in the special characteristics of this radionuclide, such as, lower energy of emissionbeta, shorter half-life as well as the emission of gamma photons, which allows its gammagraphicmonitoring. It is also a paramagnetic element, so it can be detected by means of magnetic resonance,facilitating simulation prior to treatment and its subsequent monitoring.


Matilla Peña, M.T. Chivad, A. Fernández-Simóne y M. Romerao Cristobal. Medicine. 2012; 11 (12):693-703.

Ahmadzadehfar H., Sabet A., Biermann K., Muckle M., Kuhl C., Wilhelm K., Biersack H., Ezziddin S. The Significance of 99mTc-MAA SPECT/CT Liver Perfusion Imaging in Treatment Planning for 90Y-Microsphere Selective Internal Radiation Treatment. Journal of Nuclear Medicine. 2010; 51(8), 1206-1212.

Bruha R., Dvorak K., Radan J. P. Alcoholic Liver Disease. World Journal of Hepatology. 2012; 4 (3):81-90.

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53:1020-2.

De Gersem R., Maleux G., Vanbilloen H., Baete K., Verslype C., Haustermans K., et al. Influence of time delay on the estimated lung shunt fraction on 99mTc-labeled MAA scintigraphy for 90Y microsphere treatment planning. Clinical Nuclear Medicine. 2013; 38(12), 940-942.

Sangro B., Boán J., Martínez de la Cuesta A., Kennedy, A. Irradiación hepática selectiva con microesferas cargadas con Ytrio. Oncología (Barcelona). 2004; 27(4), 106-108.

Saxena, A., Meteling, B., Kapoor, J., Golani, S., Morris, D.L., Bester, L. Is Yttrium-90 Radioembolization a Viable Treatment Option for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases? A Large Single-Center Experience of 302 Patients. Ann. Surg. Oncol. 2015; 22 (3):794-802.

Cosimelli, M., Golfieri, R., Cagol, P.P., et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br. J Cancer. 2010; 103 (3):324-331.

Maarten L J Smits, Johannes F W Nijsen, Maurice A A J van den Bosch, Marnix G E H Lam, Maarten A D Vente, Willem P T M Mali, Alfred D van het Schip, Bernard A Zonnenberg, Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Vol 13. October 2012; 1025-1034.

Nienke J. M. Klaassen1, Mark J. Arntz1, Alexandra Gil Arranja, Joey Roosen1 and J. Frank W. Nijsen. The various therapeutic applications of the medical isotope holmium-166: a narrative review. EJNMMI Radiopharmacy and Chemistry. 2019; 4:19

Sohn JH, et al. Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, largeepatocellular carcinoma. Oncology. 2009; 76(1):1–9.

Nijsen F, et al. Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study. Eur J Nucl Med. 2001; 28 (6): 743-749.

Nijsen JF, et al. Advances in nuclear oncology: microspheres for internal radionuclide therapy of liver tumours. Curr Med Chem. 2002a; 9 (1): 73-82.

Nayak D, Lahiri S. Application of radioisotopes in the field of nuclear medicine - I. lanthanide series elements. J Radioanal Nucl Chem. 1999; 242 (2):423-432.

Nijsen JFW, et al. Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Eur J Nucl Med. 1999; 26 (7):699-704.

Nijsen JF, Krijger GC, van Het Schip AD. The bright future of radionuclides for cancer therapy. Anti Cancer Agents Med Chem. 2007; 7(3):271-90.

Nethaway D, Missimer M. The half-lives of 166Ho, 167Tm, 168Tm and the 165Ho (n, ?) 166mHo cross-section. J Inorg Nucl Chem. 1968; 30(1):15-8.

Nijsen JF, et al. Liver tumors: MR imaging of radioactive holmium microspheres-phantom and rabbit study. Radiology. 2004; 231(2):491-499.

Seevinck PR, et al. Factors affecting the sensitivity and detection limits of MRI, CT, and SPECT for multimodal diagnostic and therapeutic agents. Anti Cancer Agents Med Chem. 2007; 7(3):317-34.

Bakker RC, van Es RJJ, Rosenberg AJWP, van Nimwegen SA, Bastiaannet R, de Jong HWAM, Nijsen JFW, Lam MGEH. Intratumoral injection of radioactive holmium-166 microspheres in recurrent head and neck squamous cell carcinoma: preliminary results of first use. Nucl Med Commun. 2018; 39(3):213-21.

Johnson LS, Yanch JC. Absorbed dose profiles for radionuclides of frequent use in radiation synovectomy. Arthritis Rheum. 1991; 34(12):1521-30.

Meade, V.M., Burton, M.A., Gray, B.N., Self, G.W. Distribution of different sized microspheres in experimental hepatic tumours. Eur. J. Cancer Clin. Oncol. 1987; 23, 37-41.

Pasciak, A. Handbook of Radioembolization. 2017. CRC Press, Taylor & Francis Group, LLC.

Prince, J.F., van den Bosch, M., Nijsen, J.F.W., Smits, M.L.J., van den Hoven, A.F., Nikolakopoulos, S., Wessels, F.J., Bruijnen, R.C.G., Braat, M., Zonnenberg, B.A., Lam, M. Efficacy of radioembolization with holmium-166 microspheres in salvage patients with liver metastases: a phase 2 study. J. Nucl. Med. 2017; 15, 197194.

Mumper RJ, Ryo UY, Jay M. Neutron activated holmium-166-poly (L-lactic acid) microspheres: a potential agent for the internal radiation therapy of hepatic tumours. J Nucl Med. 1991; 32: 2139–2143.

M. A. D. Vente, J. F. W. Nijsen, R. de Roos, M. J. van Steenbergen, C. N. J. Kaaijk, M. J. J. Koster-Ammerlaan, P. F. A. de Leege,W. E. Hennink, A. D. van het Schip, G. C. Krijger. Neutron activation of holmium poly (L-lactic acid) microspheres for hepatic arterial radioembolization: a validation study. Biomed Microdevices. 2009; 11:763-772. DOI 10.1007/s10544-009-9291-y.

Sander W. Zielhuis, Johannes F. W. Nijsen, Gerard C. Krijger, Alfred D. van het Schip, and Wim E. Hennink. Holmium-Loaded Poly (L-lactic Acid) Microspheres: In Vitro Degradation Study. Biomacromolecules. 2006; 7, 2217-2223.

M. Rodríguez-Fraile, y M. Iñarrairaegui. Radioembolización de tumores hepáticos con 90Y-microesferas. Rev Esp Med Nucl Imagen Mol. 2015; 34(4):244-257.

Leung WT, Lau WY, Ho SK, Chan M, Leung NW, Lin J, et al. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med. 1994; 35:70-3.

Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012; 82:401–7.

International Commission on Radiation Units and Measurements (ICRU) Tissue Substitutes in Radiation Dosimetry and Measurement (1989) ICRU report 44. ICRU, Bethesda, MD.

Elschot M, Nijsen JFW, Lam MGEH, et al. 99mTc-MAA overestimates the absorbed dose to the lungs in radioembolization: A quantitative evaluation in patients treated with (166)Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014; 41:1965-1975.

Braat AJAT, Prince JF, van Rooij R, et al: Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study. Eur Radiol. 2018; 28:920-928.

Maarten LJ Smits1, Johannes FW Nijsen, Maurice AAJ van den Bosch, Marnix GEH Lam, Maarten AD Vente, Julia E Huijbregts, Alfred D van het Schip, Mattijs Elschot, Wouter Bult, Hugo WAM de Jong, Pieter CW Meulenhoff and Bernard A Zonnenberg. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. Journal of Experimental & Clinical Cancer Research. 2010; 29:70.

Smits MLJ, Nijsen JFW, van den Bosch MAAJ, et al: Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): A phase 1, dose-escalation study. Lancet Oncol. 2012; 13:1025-1034.

Jip F. Prince, MD, Maarten L.J. Smits, MD, PhD, Gerard C. Krijger, et al: Radiation Emission from Patients Treated with Holmium-166 Radioembolization. J. Vasc. Interv. Radiol. 2014; 25:1956–1963. Elsevier Inc.

Margot T.M. Reinders, MSc, Maarten L.J. Smits, MD, Caren van Roekel, MD, and Arthur J.A.T. Braat, MD. Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. Semin Nucl Med. 2019; 49: 237-243. Elsevier Inc.


Download data is not yet available.